This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

dolutegravir/rilpivirine (Juluca®)

Reference No. 2850

Publication date:

Appraisal information

dolutegravir/rilpivirine (Juluca®) 50 mg/25 mg film-coated tablet

Company: ViiV Healthcare UK Ltd
BNF category: Infections
NMG meeting date: 07/11/2018
AWMSG meeting date: 12/12/2018
Submission Type: Full Submission
Status: Recommended
Advice No: 2218
Ratification by Welsh Government: 19/12/2018

Current Progress

Ratification by
Welsh Government

AWMSG advice

Dolutegravir/rilpivirine (Juluca®) is recommended as an option for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non­nucleoside reverse transcriptase inhibitor or integrase inhibitor. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price.
AWMSG Secretariat Appraisal Report (ASAR)
Final Appraisal Recommendation (FAR)